Insmed’s Growth Potential: Buy Rating Backed by TPIP’s Market Promise and Strong Sales Projections

Bank of America Securities analyst Jason Zemansky has maintained their bullish stance on INSM stock, giving a Buy rating on April 11.

Jason Zemansky has given his Buy rating due to a combination of factors highlighting Insmed’s potential for significant growth. Despite Insmed’s impressive performance over the past year, skepticism remains, and the stock is trading below its potential value. The company’s late-stage pipeline, particularly TPIP, is expected to generate substantial sales, with management projecting over $8 billion in peak total sales.
Zemansky points out that TPIP, a prodrug of treprostinil, offers notable advantages over its parent molecule, which is a key treatment for pulmonary hypertension. Encouraging initial phase 2 data, expert optimism, and the potential for TPIP to capture a significant market share are strong indicators of its success. Additionally, the management’s confidence in meeting and exceeding clinical benchmarks further supports the positive outlook for Insmed’s stock. These factors, combined with limited downside risk and potential upside, underpin Zemansky’s Buy rating for INSM shares.

Based on the recent corporate insider activity of 114 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of INSM in relation to earlier this year.